3 ASX Penny Stocks With Market Caps Above A$40M

Amidst a backdrop of fluctuating oil prices and a sharp sell-off in US technology stocks, the Australian market faces a complex outlook. For investors willing to explore beyond established names, penny stocks—typically smaller or newer companies—can offer intriguing opportunities. While the term may seem outdated, these stocks remain relevant as they often present unique value propositions with solid financial foundations that can provide both stability and potential for growth.

Let's take a closer look at a couple of our picks from the screened companies.

Nova Eye Medical (ASX:EYE)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Nova Eye Medical Limited is an Australian company that designs, develops, manufactures, markets, and sells surgical devices for glaucoma treatment globally with a market cap of A$42.74 million.

Operations: The company's revenue is derived from its Glaucoma Surgical Devices segment, which generated A$34.87 million.

Market Cap: A$42.74M

Nova Eye Medical Limited, with a market cap of A$42.74 million, is navigating the challenges typical for companies in its segment. The firm remains unprofitable, although it has reduced losses over the past five years and reported sales of A$34.87 million for the year ending June 30, 2026. Despite having no debt and seasoned management, Nova Eye faces liquidity concerns with less than a year of cash runway and an auditor's going concern warning. Recent reaffirmation of sales guidance suggests confidence in growth prospects outside China amid ongoing volatility in weekly returns at 8%.

• Click here to discover the nuances of Nova Eye Medical with our detailed analytical financial health report.
• Assess Nova Eye Medical's future earnings estimates with our detailed growth reports.

MaxiPARTS (ASX:MXI)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: MaxiPARTS Limited operates in Australia, distributing and selling commercial truck and trailer parts, as well as automotive tools and workshop consumables, with a market cap of A$105.58 million.

Operations: The company's revenue is derived from its MaxiPARTS Operations, which generated A$252.01 million, and Förch Australia, contributing A$23.46 million.

Market Cap: A$105.58M

MaxiPARTS Limited, with a market cap of A$105.58 million, shows promise in the penny stock arena by maintaining strong financials and growth prospects. The company's earnings have grown 13.1% over the past year, outpacing the industry average, and are forecasted to grow further at 16.2% annually. Its short-term assets exceed both short and long-term liabilities, indicating solid liquidity management. Despite a low return on equity of 8.8%, MaxiPARTS benefits from more cash than debt and high-quality earnings supported by an experienced board and management team. Recent acquisition efforts underscore strategic expansion plans despite volatility in share price movements.

• Jump into the full analysis health report here for a deeper understanding of MaxiPARTS.
• Understand MaxiPARTS' earnings outlook by examining our growth report.

SomnoMed (ASX:SOM)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SomnoMed Limited, with a market cap of A$62.63 million, produces and sells devices for the oral treatment of sleep-related disorders across the Asia Pacific region, North America, and Europe.

Operations: The company generates A$114.53 million in revenue from its production and sale of products designed to treat sleep disordered breathing.

Market Cap: A$62.63M

SomnoMed Limited, with a market cap of A$62.63 million, presents a mixed picture in the penny stock landscape. While unprofitable and reporting a net loss of A$2.65 million for fiscal year 2026, the company has made strategic strides by reducing its debt to equity ratio from 7.3% to 0.9% over five years and maintaining positive free cash flow with a runway exceeding three years if stable conditions persist. The recent launch of VirtusTM targets an underserved market segment, potentially bolstering revenue growth ambitions alongside planned acquisitions and operational enhancements under seasoned board leadership.

• Dive into the specifics of SomnoMed here with our thorough balance sheet health report.
• Gain insights into SomnoMed's future direction by reviewing our growth report.

Summing It All Up

• Unlock our comprehensive list of 423 ASX Penny Stocks by clicking here.
• Searching for a Fresh Perspective? These 21 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com